From: Emerging treatment modalities for systemic therapy in hepatocellular carcinoma
Checkpoint inhibitors | Phase | Patients (No.) | Clinical setting | Status | NCT numbers |
---|---|---|---|---|---|
Nivolumab + Ipilimumab | I/II | 32 | Child-Pugh A HCC | Recruiting | |
Nivolumab + Ipilimumab | I | 50 | Unresectable HCC with Child Pugh Class A cirrhosis | Active, not recruiting | |
Nivolumab + Ipilimumab | II | 30 | HCC with potential surgical resection | Active, not recruiting | |
Nivolumab + Ipilimumab | III | 650 | Advanced HCC without prior systemic therapy | Recruiting | |
Nivolumab + Ipilimumab | II | 40 | HCC with potential for curative surgical resection | Recruiting | |
Nivolumab + Mogamulizumab | I | 96 | locally advanced or metastatic solid tumors | Completed | |
Nivolumab + Relatlimab | I | 20 | Potentially resectable HCC | Not yet recruiting | |
Pembrolizumab + Bavituximab | II | 28 | Locally advanced or metastatic HCC not amenable to locoregional therapy | Recruiting | |
Durvalumab+ Tremelimumab | III | 1504 | Unresectable HCC without prior systemic therapy | Recruiting | |
Durvalumab+ Tremelimumab | I | 32 | Unresectable, locally advanced liver cancer after radioembolization | Suspended | |
Durvalumab+ Tremelimumab | II | 433 | Advanced HCC | Active, not recruiting |